Supplementing FTR #1138, this program continues discussion about drug treatments for, and vaccines to prevent, Covid-19.
In previous posts and programs, we have noted that Moderna’s vaccine work has been financed by DARPA. We have also noted that the overall head of Operation Warp Speed is Moncef Slaoui, formerly in charge of product development for Moderna!
Of great significance is the central role of the military in the development of treatment for Covid-19:
1.–The program notes that: ” . . . . Remdesivir predates this pandemic. It was first considered as a potential treatment for Ebola, and was developed through a longstanding partnership between the U.S. Army and the Centers for Disease Control and Prevention. . . .”
2.–Jonathan King has sounded the alarm about “vaccine research” masking offensive biological warfare research: “. . . . King, who has chaired the microbial physiology study section for the NIH, believes that without intensive independent scrutiny, the Pentagon is free to obscure its true goals. ‘The Defense Department appears to be pursuing many narrow, applied goals that are by nature offensive, such as the genetic ‘improvement’ of BW agents,’ King says. ‘But to achieve political acceptability, they mask these intentions under forms of research, such as vaccine development, which sound defensive. . . .”
3.–Moderna’s vaccine development was overseen by an unnamed Pentagon official: ” . . . . Moderna’s team was headed by a Defense Department official whom company executives described only as ‘the major,’ saying they don’t know if his name is supposed to be a secret. . . . .”
4.–The pervasive role of the military in Operation Warp Speed (the Trump administration’s vaccine development program) has generated alarm in civilian participants: “. . . . Scores of Defense Department employees are laced through the government offices involved in the effort, making up a large portion of the federal personnel devoted to the effort. Those numbers have led some current and former officials at the Centers for Disease Control and Prevention to privately grumble that the military’s role in Operation Warp Speed was too large for a task that is, at its core, a public health campaign. . . .”
5.–General Gustave Perna–one of the principals in Operation Warp Speed–has chosen a retired Lieutenant General to oversee much of the program: ” . . . . ‘Frankly, it has been breathtaking to watch,’ said Paul Ostrowski, the director of supply, production and distribution for Operation Warp Speed. He is a retired Army lieutenant general who was selected to manage logistics for the program by Gen. Gustave F. Perna, the chief operating officer for Operation Warp Speed. . . .”
6.–The military will be able to trace the destination and administration of each dose: ” . . . . Military officials also came up with the clever idea — if it works — to coordinate the delivery of vaccines to drugstores, medical centers and other immunization sites by sending kits full of needles, syringes and alcohol wipes. Vaccine makers will be alerted when the kits arrive at an immunization site so they know to ship doses. Once the first dose is given, the manufacturer will be notified so it can send the second dose with a patient’s name attached several weeks later. The military will also monitor vaccine distribution through an operations center. ‘They will know where every vaccine dose is,’ Mr. [Paul] Mango said on a call with reporters. . . .”
This program begins with information about the ongoing professional massaging of Gilead Sciences’ anti-viral remdesivir.
The most positive studies have proved remdesivir/Veklury only modestly successful against SARS Cov-2 (the virus that causes Covid-19). Remdesivir (now marketed under the brand name Veklury) has been propelled to the forefront of treatment regimens for the pandemic, a development which appears to diminish the chances for a competing, more effective drug to gain professional approval for treating Covid-19.
” . . . . Other studies have shown no benefit, including the World Health Organization’s Solidarity trial, released as a preprint on Oct. 15. Based on these results, the European Society of Intensive Care Medicine is now recommending that the drug not be routinely used in hospitalized Covid-19 patients. Infectious disease experts have stated that after examining all available evidence, we can reasonably conclude only that remdesivir may work. . . .”
Deeply disturbing, as well, is the news that the “positive news” about vaccine success and development has been generated by press releases from the companies that manufacture them: ” . . . . But the companies announced the findings in news releases, not in peer-reviewed scientific journals, and did not disclose the detailed data that would allow outside experts to evaluate their claims. Therefore, the results cannot be considered conclusive. The figures on effectiveness may change as the studies continue. . . .”
Program Highlights Include: The rapid spread of the disease is benefitting the speed-up of vaccine research; review of the attenuated, manipulated NIAID study on remdesivir that generated positive news, a run-up in the stock price of Gilead Sciences and a boost for the market as a whole; review of the role of “Scientists to Stop Covid-19” in massaging the vetting process for remdesivir; review of the CDC’s closing of the USAMRIID in August of 2019 and the testing of remdeisivir at that facility in March of 2019; review of the insidious, incestuous relationship between the authorities “regulating” treatment of Lyme Disease and those who benefit from the administration of that treatment; review of Lyme Disease as a biological warfare weapon.